Did you know that titanium is the most commonly used material in bone surgery?
Due to its high strength, low weight, high corrosion resistance and excellent biocompatibility, titanium is an ideal application material in medicine…
INICELL® represents the further development of the sandblasted and thermal acid etched Thommen surface.
Due to slight changes in surface chemistry, the implant surface is transferred from a hydrophobic state to a superhydrophilic surface condition (INICELL®).
These properties of INICELL® promote spontaneous and complete wetting of the implant with physiological fluids, especially blood (Tugulu 2010).
This accelerates the wound healing cascade (Milleret 2011, Burkhardt 2016, Burkhardt 2017), which is reflected in higher bone to implant contact and higher implant stability in the early healing phase.
From a clinical point of view, this results in a low early failure rate (0.5%, Le Gac 2015) and a safe and predictable treatment option after three weeks (Hicklin 2015, Hinkle 2014).
A shortened healing time can also be achieved in patients with reduced bone quality (Grades 3 and 4) (Held 2014).
APLIQUIQ® is the fast and effective chairside conditioning system used to produce the superhydrophilic INICELL® surface.
The APLIQUIQ® container contains the conditioning agent, implant and healing cap. For outstanding product development and design, Thommen Medical AG has been honored with the distinguished reddot design product award 2011. APLIQUIQ® was selected by the reddot committee based on the product’s practical design, useful functionality and innovative technology.
Many consider the sandblasted, thermal acid-etched microrough surface to be the gold standard for implant surface modification.
The advantage for implants that feature a microrough surface is that they establish excellent functional and structural connections between the bone and the implant surface, leading to higher intrinsic implant stability (Buser 1999).
Specifically, the microrough surface enhances the interlocking of the implant surface with bone and has been shown to promote the differentiation of osteogenic cells in-vitro (Boyan 2001).
The improved and uniform adsorption of proteins from the blood promotes the subsequent healing process.
Surface energy and hydrophilicity play a crucial role in the primary interaction of an implant with its physiological environment (Brodbeck 2002). This interaction begins immediately upon the first blood contact, in the form of rapid adsorption of a film of plasma proteins. INICELL® (right) exhibits a complete and homogenous protein film, indicating full contact with the physiological protein solution. The unconditioned surface (left) shows a nonhomgenous protein film. The result suggests advantageous primary contact and protein adsorption for INICELL® (Tugulu 2010).
Fluorescence microscopic picture of the protein film on model substrates five minutes after primary contact with protein solution.
The quantity, composition, homogenity and functionality of the protein film deposited on the implant surface directly influences the healing and osseointegration processes to follow.
Boyan B et al. Titanium in medicine. Brunette DM et al. (eds.) Springer, 2001: 562-79.
Brodbeck W. G., et al., J. M. Proc. Natl. Acad. Sci. USA 2002; 99, 10: 287-292.
Burkhardt M, Gerber I, Moshfegh C, Lucas M, Waser J, Emmert M Y, Hoerstrup S P, Schlottig F, Vogel V. Biomat. Sci. 2017, doi: 10.1039/c7bm00276a.
Burkhardt M A, Waser J, Milleret V, Gerber I, Emmert M Y, Foolen J, Hoerstrup S P, Schlottig F, Vogel V. Nature, Scientific Reports, 6:21071.
Buser D, Nydegger T, Oxland T, Cochran DL, Schenk RK, Hirt HP, Snétivy D, Nolte LP. J Biomed Mater Res. 1999; 45(2): 75-83.
Calvo-Guirado JL, Ortiz-Ruiz AJ, Negri B, López-Marí L, Rodriguez-Barba C, Schlottig F. Clinical Oral Implants Research 21, no. 3 (2010): 308-15.
Derks J, Håkansson J, WennströmJL, Tomasi C, Larsson M, Berglundh T. JDR March 94 no. 3 suppl (2015): 44-51.
van Eekeren P, Tahmaseb A, Wismeijer D. Clinical Oral Implants Research 0, (2015): 1-6.
Held U, Rohner D, Rothamel D. Head and Face Medicine 9, no. 37 (2013): 1-9.
Hinkle RM, Rimer SR, Morgan MH, Zeman P. Journal of Oral and Maxillofacial Surgery 72 no. 8 (2014): 1495-1502.
Le Gac O, Grunder U. Dentistry Journal, no 3 (2015): 15-23.
Milleret V, Tugulu S, Schlottig F, Hall H. European Cells and Materials 21 (2011): 430-44.
Stadlinger B, Lode AT, Eckelt U, Range U, Schlottig F, Hefti T, Mai R. Journal of Clinical Periodontology 36, no. 10 (2009): 882-891.
Stadlinger B, Ferguson SJ, Eckelt U, Mai R, Lode AT, Loukota R, Schlottig F. The British Journal of Oral & Maxillofacial Surgery 50, no. 1 (2012): 74-9.
Tugulu S, Löwe K, Scharnweber D, Schlottig F. Journal of Materials Science Materials in Medicine 21, no.10 (2010): 2751-2763.
Tugulu S, Hall H, Schlottig F. Clinical Oral Implants Research 20, no. 9 (2009): 1024-25 (poster no. 376).
Vasak C, Busenlechner D, Schwarze UY, Leitner HF, Munoz Guzon F, Hefti T, Schlottig F, Gruber R. Clinical Oral Implants Reserach 25, no. 12 (2014) 1378-85.